A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study

被引：7
作者：
Plaxe, SC
Blessing, JA
Olt, G
Husseinzadah, N
Lentz, SS
DeGeest, K
Valea, FA
机构：
[1] Univ Calif San Diego, Med Ctr, Dept Reprod Med, San Diego, CA 92103 USA
[2] Roswell Pk Canc Inst, Gynecol Oncol Grp, Buffalo, NY 14263 USA
[3] Penn State Univ, Milton S Hershey Med Ctr, Dept Obstet & Gynecol, Hershey, PA 17033 USA
[4] Univ Cincinnati, Dept Obstet & Gynecol, Div Oncol, Cincinnati, OH 45267 USA
[5] Wake Forest Univ, Bowman Gray Sch Med, Dept Obstet & Gynecol, Gynecol Oncol Sect, Winston Salem, NC 27157 USA
[6] Rush Med Coll, Dept Gynecol Oncol, Chicago, IL 60612 USA
[7] SUNY Stony Brook, Dept Obstet & Gynecol & Reprod Med, Stony Brook, NY 11794 USA
来源：
CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2002年 / 50卷 / 02期
关键词：
PZA; pyrazoloacridine; cervical cancer;
D O I：
10.1007/s00280-002-0470-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Purpose: The Gynecologic Oncology Group performed a phase II study to determine the response rate to pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix. Methods: PZA was administered intravenously over 3 h every 3 weeks. A dose of 760 mg/m(2) was given to the first 11 patients and was reduced to 560 mg/m(2) for subsequent patients. The dose reduction was undertaken because of unexpected severe neutropenia among the initial patients. Results: Among 24 evaluable patients, 21 of whom had prior chemotherapy, there was one, brief, complete response (4.2%) and no partial responses. The major toxicity was neutropenia. Conclusion: PZA at the dose and schedule employed, has insignificant activity in this population.
引用
收藏
页码：151 / 154
页数：4
相关论文
共 19 条
[1]   Current status of pyrazoloacridine as an anticancer agent [J].
Adjei, AA .
INVESTIGATIONAL NEW DRUGS, 1999, 17 (01) :43-48
[2]  
Adjei AA, 1998, CLIN CANCER RES, V4, P683
[3]   Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: A gynecologic oncology group study [J].
Bloss, JD ;
Blessing, JA ;
Behrens, BC ;
Mannel, RS ;
Rader, JS ;
Sood, AK ;
Markman, M ;
Benda, J .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) :1832-1837
[4]   Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma [J].
Dodd, PM ;
McCaffrey, JA ;
Mazumdar, M ;
Icasiano, E ;
Higgins, G ;
Herr, H ;
Bajorin, DF .
INVESTIGATIONAL NEW DRUGS, 2000, 18 (03) :247-251
[5]  
LoRusso P, 1995, CLIN CANCER RES, V1, P1487
[6]  
MOORE DH, 2001, P AN M AM SOC CLIN, V20, P801
[7]   Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: A gynecologic oncology group study [J].
Omura, GA ;
Blessing, JA ;
Vaccarello, L ;
Berman, ML ;
ClarkePearson, DL ;
Mutch, DG ;
Anderson, B .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) :165-171
[8]   RADIATION-THERAPY ALONE IN THE TREATMENT OF CARCINOMA OF THE UTERINE CERVIX - A 20-YEAR EXPERIENCE [J].
PEREZ, CA ;
CAMEL, HM ;
KUSKE, RR ;
KAO, MS ;
GALAKATOS, A ;
HEDERMAN, MA ;
POWERS, WE .
GYNECOLOGIC ONCOLOGY, 1986, 23 (02) :127-140
[9]   Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: A gynecologic oncology group study [J].
Plaxe, SC ;
Blessing, JA ;
Husseinzadeh, N ;
Webster, KD ;
Rader, JS ;
Dunton, CJ .
GYNECOLOGIC ONCOLOGY, 2002, 84 (02) :241-244
[10]   Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study [J].
Plaxe, SC ;
Blessing, JA ;
Bookman, MA ;
Creasman, WT .
GYNECOLOGIC ONCOLOGY, 2002, 84 (01) :32-35
12